PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 0.00.
Virada para Prejuízo
O desempenho da empresa passou a ser negativo, com prejuízo anual mais recente de US$ .
Avaliação Justa
O PE mais recente da empresa é -0.65, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 1.07M ações, um aumento de 24.50% em relação ao trimestre anterior.
Mantido por James Simons
O Super Investidor James Simons possui 0.00 ações desta empresa.